ClinConnect ClinConnect Logo
Search / Trial NCT06882317

Long Term Follow-up Study for Subjects Administered CLBR001

Launched by CALIBR, A DIVISION OF SCRIPPS RESEARCH · Mar 12, 2025

Trial Information

Current as of April 23, 2025

Not yet recruiting

Keywords

Long Term Follow Up (Ltfu) Clbr001 Autologous Cell Therapy Switchable Car T Cell Cell And Gene Therapy

ClinConnect Summary

In line with FDA guidance on Long Term Follow-Up (LTFU) after administration of human gene therapy products, any subject who receives CLBR001 on any Calibr treatment study will participate in LTFU on this study. Subjects will be enrolled following completion on the applicable treatment study and followed for 15 years post-CLBR001 administration in order to assess the long term safety of CLBR001.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Subjects who received at least one CLBR001 cell dose.
  • Exclusion Criteria:
  • None

Trial Officials

Chief Medical Officer

Study Director

Calibr-Skaggs Institute for Innovative Medicines

About Calibr, A Division Of Scripps Research

Calibr, a division of Scripps Research, is a pioneering biotechnology organization dedicated to advancing the discovery and development of transformative therapies. Leveraging cutting-edge science and innovative technologies, Calibr focuses on translating high-impact research into clinically viable solutions for unmet medical needs. The organization collaborates with academic institutions, industry partners, and clinical investigators to accelerate the progress of novel treatments, particularly in the fields of immunology, oncology, and regenerative medicine. With a commitment to excellence and a patient-centered approach, Calibr aims to improve health outcomes and enhance the quality of life for patients worldwide.

Locations

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported